Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8647604 | Multiple Sclerosis and Related Disorders | 2018 | 5 Pages |
Abstract
Patients treated with Interferon-β1a 44 mcg presented with a marginally reduced risk of disability accrual in the long-term, when compared with Interferon-β1b 250 mcg and, at least in part, with Interferon-β1a 30 mcg. Formulation, frequency of administration and dose of Interferon-β might affect the long-term clinical evolution of RRMS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Marcello Moccia, Raffaele Palladino, Antonio Carotenuto, Francesco Saccà , Cinzia Valeria Russo, Roberta Lanzillo, Vincenzo Brescia Morra,